secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061121
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q3 net loss $49.9M ($1.16/share); goodwill impairment of $19.5M
--------------------------------------------------------------------------

- Revenue not reported; R&D expenses $26.2M vs $16.6M YoY; G&A $6.6M vs $6.4M.
- Cash $183.3M at Sept 30 2023, down from $257.7M at Dec 31 2022; runway into H1 2025.
- Initiated ADI-001 EXPAND cohort in post-CAR T LBCL; MCL enrollment continues.
- Prioritizing ADI-270 for solid tumors; IND filing expected H1 2024; paused ADI-925.
- Goodwill fully impaired by $19.5M following impairment test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023061121/0000950170-23-061121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023061121/acet-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer